The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
HOME > BUSINESS
BUSINESS
- Takeda’s Relugolix Hits Primary Endpoint in Uterine Fibroids-Tied Pain: Japan PIII
November 10, 2017
- Ono Links Arms with Neurimmune on Neurodegenerative Disease
November 10, 2017
- Gilead’s VP for EMEA Hermans to Replace Orihara as Japan Head
November 10, 2017
- Can Japan’s 1st Enbrel Biosimilar Make Its Mark in RA Follow-On Arena with Self-Injection?
November 10, 2017
- Kyorin Pres. Says AG Strategy Is a “Success,” Nasonex Eyed as 2nd Battlefield
November 9, 2017
- Takata Seiyaku to Take Over MA for MSD’s Gentacin
November 9, 2017
- Mitsubishi Tanabe Grabs Distribution Rights to Clenafin/Jublia in Taiwan
November 9, 2017
- Top Court Dismisses Elplat Patent Infringement Case: Nichi-Iko
November 9, 2017
- Takeda Teams Up with US Medical Device Company to Develop Needle-Free Injection Device Utilizing Pressurized Liquid
November 9, 2017
- Evocalcet Shows Non-Inferiority to Regpara in Japan PIII
November 8, 2017
- Tolvaptan Re-Submitted to US FDA for ADPKD: Otsuka
November 8, 2017
- Santen Will Derive More than 30% of Sales Overseas This Fiscal Year: President
November 8, 2017
- Bayer to Put Digital Technology Proposals to Practical Use; AI-Based Automated Coding Will Reduce Workload by 40%
November 8, 2017
- Opdivo’s Half-Year Sales Sag as 50% Price Cut Takes Toll: Ono
November 7, 2017
- 4 Japan Drug Majors See Half-Year Profit Fall on One-Off Factors, but Global Flagships Thrive
November 7, 2017
- Pfizer Adjusts Shipments of Selara, Others Due to Damage Caused by Hurricane
November 7, 2017
- JCR Side Asked GSK to Revise Capital Alliance: CEO Ashida
November 6, 2017
- Mitsubishi Tanabe to Acquire Stelic, Adding Nucleic Acid Drugs to Lineup to Accelerate Business Development in US
November 6, 2017
- Shionogi, UMN Pharma Conclude Capital Alliance; Tie Up in Infectious Disease Field
November 2, 2017
- Kirin, Amgen Wind Up Drug Development Joint Venture
November 2, 2017
ページ
The pharmaceutical industry is ever-changing. Recruiters must evolve accordingly and prepare well in advance for future talent needs.This means predicting the changes and trends that will impact the market, industry, and your organization, and how this will affect talent requirements.…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…